(3S,4R)-3-Ethyl-4-[3-[4-Methyphenyl)Sulfonyl]-3H-Imidazo[1,2-A]Pyrrolo[2,3-E]Pyrazin-8-Yl]-Pyrrolidinecarboxylic Phenylmethyl Ester

During the scale-up of a selective PI3Kδ inhibitor for relapsed follicular lymphoma, process development engineers encountered a critical bottleneck at the key C-N coupling step involving the (3S,4R)-pyrrolidine intermediate. The compound’s 3-ethyl substituent creates steric compression at the β-face of the pyrrolidine ring, which, when combined with the electron-withdrawing 4-methylphenylsulfonyl group on the imidazo[1,2-a]pyrrolo[2,3-e]pyrazine core, renders the α-proton at C-2 susceptible to base-mediated epimerization at temperatures exceeding 8°C in aprotic solvents. Production batches manufactured under ICH Q7 Section 7.31 (cleaning validation) and 21 CFR 210.3(b)(4) (designated starting material) require the intermediate to be charged at 1.02–1.08 molar equivalents in the Buchwald–Hartwig amination with the corresponding aryl bromide, using a Pd₂(dba)₃/XPhos catalyst system in toluene at 45±2°C for 6 h. Deviation beyond 1.10 equivalents triggers formation of the undesired (3S,4S)-diastereomer, which co-elutes with the target API during reverse-phase chromatography (Kromasil C18, 5 μm, 250×4.6 mm) under the validated method per USP \<621\>. Downstream, the crude product is telescoped into a two-step sequence—hydrogenolytic cleavage of the phenylmethyl ester over 10% Pd/C (50% wet) at atmospheric pressure, followed by isolation of the free acid as an N-methyl-D-glucamine salt to achieve ≥99.5% ee and <0.15% single impurity by HPLC. Final formulated drug product is an immediate-release tablet containing 25 mg of the phosphate salt, direct-compressed with Avicel PH-102, crospovidone, and magnesium stearate in a Romaco Kilian KTP 420X press operating at 85 kN compression force, with in-process controls for disintegration time (≤15 min in 0.1 N HCl at 37°C, USP \<701\>) and content uniformity (ASTM E2709-19).

Can This Intermediate Tolerate Palladium-Catalyzed Cross-Coupling Without Epimerization at C-4?

In the preparation of heterobifunctional PROteolysis TArgeting Chimeras (PROTACs) that employ a cereblon E3 ligase ligand linked to a BRD4 bromodomain inhibitor, the phenylmethyl ester serves as a hinge-binder fragment that must survive Suzuki–Miyaura coupling at a late stage. The intrinsic lability of the C-4 stereocenter—positioned α to the pyrrolidine nitrogen—is exacerbated when the reaction mixture is exposed to aqueous carbonate bases at pH >9.5. Process characterization data from a 20 L jacketed reactor (GMM Pfaudler, glass-lined, thermal fluid -25 to 200°C) indicate that a solvent system of 2-MeTHF:water (4:1 v/v) with 2.5 eq of K₃PO₄ and 0.5 mol% Pd(dppf)Cl₂·CH₂Cl₂ maintains the (3S,4R) configuration at 98.7% diastereomeric excess when the internal temperature is held at 55±3°C for 90 minutes. Exceeding 60°C under otherwise identical conditions raises the (3S,4S)-epimer to 4.8 area%, rendering the batch unrecoverable by simulated moving bed (SMB) chromatography. Regulatory filings under ICH M7(R2) for potentially mutagenic impurities require a dedicated LC-MS/MS purge factor study (LOQ 0.1 ppm) for residual palladium and the ring-opened byproduct arising from imidazole hydration; the intermediate is therefore typically charged at a controlled 1.00±0.03 equivalent relative to the boronic acid pinacol ester coupling partner to minimize excess reagent carryover. Following aqueous workup with 5% N-acetylcysteine in 1 M NaCl for palladium scavenging, the coupled product is precipitated from MTBE/n-heptane (1:3 v/v) to deliver a white solid with ≤50 ppm Pd by ICP-OES (USP \<233\>). The final degrader molecule is formulated as an amorphous solid dispersion (HPMCAS-MG, 20% drug load) by hot-melt extrusion on a twin-screw extruder (Thermo Fisher Pharma 11, L/D 40:1, barrel temperature 160–175°C) and encapsulated into size 0 HPMC capsules for oral administration in oncology clinical trials.

For multi-kilogram deliveries of an antiviral nucleoside prodrug targeting hepatitis C virus NS5B polymerase, the phenylmethyl ester is deployed as a masked carboxylate surrogate that can be selectively deprotected in the presence of a phosphoramidate prodrug moiety. The sulfonyl-pyrrolopyrazine ring system imparts exceptionally low aqueous solubility (<5 μg/mL in FaSSIF buffer, pH 6.5) yet high permeability (P_app >20×10^-6 cm/s in Caco-2 monolayers), which dictates that all downstream operations from this intermediate onward must handle the API as a micronized suspension. The intermediate is fed into the final convergent assembly at 0.98–1.02 eq in a two-phase system of dichloromethane and 50 mM phosphate buffer pH 7.0, where the activated pentafluorophenyl ester couples to the 5’-amino-2’-C-methylcytidine scaffold with 93% isolated yield after 18 h at 20–25°C. Residual water content in the phenylmethyl ester crystals must be controlled to <0.2% (Karl Fischer, USP \<921\> Method Ic) to avoid hydrolysis during the coupling, and the particle size distribution (D₉₀ <50 μm) is verified by laser diffraction (ISO 13320:2020) on a Malvern Mastersizer 3000 before batch release. GMP manufacture per ICH Q7 Section 12 requires process validation across three consecutive commercial-scale lots, each 15–20 kg input of the chiral intermediate, with strict attention to the cryogenic lithiation step that sets the C-3 ethyl configuration using (R,R)-DACH ligand in THF at -78°C. The final drug substance is lyophilized from a 40% tert-butanol cosolvent system in an IMA Edwards LYOMAX chamber (shelf temperature ramped from -40°C to +25°C at 0.1°C/min) to yield a white lyophilized cake containing the phosphate prodrug at 100 mg/vial. Terminal sterilization is not possible; therefore aseptic processing validated according to EU GMP Annex 1 is employed, with media fills performed every 6 months.

When Heterocyclic Core Modifications Demand Orthogonal Protecting Group Strategies

Exploratory chemistry efforts toward a negative allosteric modulator of metabotropic glutamate receptor 2 (mGlu₂) required a densely functionalized intermediate that could withstand sequential transformations at the imidazole C-2 and the pyrrolidine nitrogen without premature loss of the benzyl ester. The phenylmethyl ester was integrated into the synthetic sequence as a latent carboxylic acid following a chemoselective Suzuki coupling at the 8-bromo-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine core, a transformation that necessitates Boc protection of the pyrrolidine NH to prevent catalyst poisoning. Deprotection with 4 N HCl in dioxane at 0°C to 10°C cleanly removed the Boc group while leaving the benzyl ester intact, as monitored at λ=254 nm by UPLC (ACQUITY BEH C18, 1.7 μm, 50×2.1 mm). Addition of the unprotected intermediate in the subsequent reductive amination with 4-fluorobenzaldehyde was set at 1.0 equivalent with sodium triacetoxyborohydride (1.5 eq) in dichloroethane at room temperature, achieving a 92% conversion after 2 h; excess reagent led to N-benzyl over-alkylation detectable at m/z 658.2 [M+H]⁺. The final API batch is subjected to rigorous elemental impurity testing per ICH Q3D for Class 1 metals (Cd, Pb, As, Hg) with limits of ≤2 ppm oral PDE, and the residual solvent profile is cleared against USP \<467\> Option 2 for dichloromethane (≤600 ppm) and dioxane (≤380 ppm). The formulated drug product is a hard gelatin capsule containing 5 mg of the micronized active compound blended with lactose monohydrate (Pharmacopeia grade) and sodium stearyl fumarate, encapsulated on a Zanasi 40E machine at 70,000 capsules/h with weight variation of ±3%. Dissolution testing uses USP Apparatus II at 50 rpm in 900 mL of pH 4.5 acetate buffer, with a Q-value specification of ≥80% at 30 min.

For the manufacture of an auristatin-based antibody-drug conjugate (ADC) payload currently in Phase II trials for HER2-positive gastric cancer, this phenylmethyl ester served as the critical C-terminal building block that introduces the (3S,4R) stereochemistry into the dolastatin 10 analogue. The payload intermediate must meet exceptionally stringent Class 5 cytotoxic compound handling requirements (Safebridge Category 3) and is processed exclusively within a closed isolator system with ≤1 ng/m³ airborne exposure limit. The compound is charged at 1.15 equivalents in a DIC/HOBt-mediated coupling to the dipeptide warhead in DMF at -5°C to 0°C over 16 h, followed by quenching with 0.1 M acetic acid and extraction with 2-MeTHF. Critical quality attributes include residual solvents conforming to ICH Q3C Option 1 limits, palladium content <10 ppm (USP \<233\>), and an optical purity of ≥99.8% ee as determined by SFC (Chiralpak AD-H, 250×4.6 mm, 40% methanol in CO₂, 3 mL/min). The final payload is conjugated to trastuzumab via a cathepsin B-cleavable valine-citrulline linker at a drug-to-antibody ratio (DAR) of 3.8–4.2, monitored by hydrophobic interaction chromatography (TSKgel Butyl-NPR) with 214 nm detection. The lyophilized ADC formulation contains 20 mg/mL upon reconstitution with water for injection, stabilized in 20 mM histidine buffer pH 5.8 with 6% trehalose dihydrate and 0.02% polysorbate 20, packaged in 50 mg single-use vials. All manufacturing steps comply with 21 CFR Part 211 and ICH Q5A(R2) for viral safety, with a hold-time study validating 36-month shelf life at 2–8°C in the primary container closure.